Medical artificial intelligence (AI) company Lunit (328130.KQ) has launched an AI-based PD-L1 biomarker solution with Leica Biosystems, a global leader in cancer diagnostics and digital pathology, the company said on the 27th.
Lunit and Leica signed a partnership agreement in March of this year to jointly develop digital pathology solutions. As the first outcome of that collaboration, the companies have launched "Lunit SCOPE PD-L1 CAL10," a solution that explores and analyzes the PD-L1 biomarker in non-small cell lung cancer for research purposes.
The solution is optimized for Leica's PD-L1 antibody "CAL10" and provides rapid, quantitative analysis of the lung cancer biomarker PD-L1 CAL10. It is designed to reduce evaluation variability among readers and shorten diagnosis and analysis times, thereby enhancing consistency and efficiency.
Lunit SCOPE PD-L1 CAL10 can be deployed immediately through an integrated workflow linked to Leica's Aperio GT 450 digital pathology scanner.
"With this product launch, we are able to support seamless biomarker analysis workflows in digital pathology research environments," said Karan Arora, Senior Vice President of Advanced Analytics, AI and Pharma Partnerships at Leica. "Our long-term goal is to help researchers utilize AI solutions more efficiently."
"Through this collaboration, we will continue to expand the application of AI-based biomarker solutions in the field of digital pathology research," said Brandon Suh, CEO of Lunit. "We plan to use this AI solution launch as a stepping stone to further strengthen our position in the global digital pathology and precision oncology markets."
Meanwhile, Lunit's first-quarter revenue on a consolidated basis came in at 24 billion won, up 25% from a year earlier. Overseas revenue rose 29% year-on-year to 23.2 billion won, accounting for 97% of total revenue and driving the performance. Revenue from the cancer diagnostics business segment increased 22% from the same period last year to 22.3 billion won.
